The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Publications
Staniek J, Rizzi M. 2025. Signaling Activation and Modulation in Extrafollicular B Cell Responses. Immunol Rev. 330(1):e70004. doi: 10.1111/imr.70004.
Lösslein AK, Henneke P. 2025. Macrophage Differentiation and Metabolic Adaptation in Mycobacterial Infections. 2025. Annu Rev Immunol. doi: 10.1146/annurev-immunol-082323-120757.
Felixberger PT, Andrieux G, Maul-Pavicic A, Goldacker S, Harder I, Gutenberger S, Landry JJM, Benes V, Jakob TF, Boerries M, Nitschke L, Voll RE, Warnatz K, Keller B. 2025. CD21low B cells reveal a unique glycosylation pattern with hypersialylation and hyperfucosylation. Front Immunol. 16:1512279. doi: 10.3389/fimmu.2025.1512279.
Chandrasekaran P, Krausz M, Han Y, Mitsuiki N, Gabrysch A, Nöltner C, Proietti M, Heller T, Grou C, Calderon V, Subramanian P, Jones DR, Siu Y, Deming C, Conlan S, Holland SM, Segre JA, Uzel G, Grimbacher B, Falcone EL. 2025. The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency. Microbiome. 13(1):51. doi: 10.1186/s40168-025-02028-7.
Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. 2025. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency,
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
